Schonfeld Strategic Advisors’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-290,416
| Closed | -$4.39M | – | 3352 |
|
|
2022
Q3 | $4.39M | Buy |
+290,416
| New | +$3.38M | 0.04% | 571 |
|
|
2022
Q1 | – | Sell |
-17,900
| Closed | -$126K | – | 3095 |
|
|
2021
Q4 | $126K | Buy |
+17,900
| New | +$187K | ﹤0.01% | 1844 |
|
|
2020
Q3 | – | Sell |
-27,256
| Closed | -$402K | – | 1764 |
|
|
2020
Q2 | $402K | Buy |
+27,256
| New | +$403K | 0.01% | 888 |
|
|
2020
Q1 | – | Sell |
-180,148
| Closed | -$4.35M | – | 1641 |
|
|
2019
Q4 | $4.35M | Buy |
180,148
+92,248
| +105% | +$1.91M | 0.11% | 216 |
|
|
2019
Q3 | $1.69M | Buy |
+87,900
| New | +$2.01M | 0.05% | 342 |
|
|
2017
Q4 | – | Sell |
-11,801
| Closed | -$574K | – | 932 |
|
|
2017
Q3 | $574K | Buy |
+11,801
| New | +$644K | 0.05% | 358 |
|
|
2017
Q2 | – | Sell |
-7,498
| Closed | -$340K | – | 828 |
|
|
2017
Q1 | $340K | Sell |
7,498
-34,096
| -82% | -$1.52M | 0.03% | 444 |
|
|
2016
Q4 | $1.57M | Buy |
41,594
+18,363
| +79% | +$694K | 0.2% | 148 |
|
|
2016
Q3 | $877K | Buy |
23,231
+11,241
| +94% | +$248K | 0.15% | 197 |
|
|
2016
Q2 | $211K | Buy |
+11,990
| New | +$194K | 0.05% | 374 |
|
Schonfeld Strategic Advisors's AERI Position: Q4 2022 in Review
Schonfeld Strategic Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 290,416 shares — an estimated $4.39M sold.
Schonfeld Strategic Advisors first reported a position in AERI in Q2 2016 and held it in 10 quarters. The position peaked at $4.39M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Schonfeld Strategic Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 290,416 Aerie Pharmaceuticals shares in Q4 2022, an estimated $4.39M.
- Schonfeld Strategic Advisors first reported a position in Aerie Pharmaceuticals in Q2 2016 and held it in 10 quarters.
- Schonfeld Strategic Advisors's Aerie Pharmaceuticals position peaked at $4.39M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.